Generex Biotechnology Announces Interview with Richard Purcell EVP of R&D on the Yo! Dr.Yo Show with an Update on the Ii-Key COVID Vaccine Program

Livestream Interview on Friday November 13 at 2 PM EST

MIRAMAR, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (OTCQB:GNBT) today announced that Richard Purcell, Executive Vice President of Research & Development at Generex and NuGenerex Immuno-Oncology will be featured on the Yo! Dr. Yo Show to provide an update on the company’s COVID-19 vaccine development program. The interview will be live streamed at 2:00 PM on Friday, November 13, 2020 at can be heard at the following link:

https://streamyard.com/6pykxvt9m4

The Yo! Dr. Yo show is hosted by Dr. Ram Yogendra, MD, PhD, a board-certified anesthesiologist specializing in physiology and biometrics. He founded ECA Wellness to apply modern science and technology in order to offer a science-based approach to exercise, diet, and health through on-line collaboration with patients. Dr. Yogendra has built a loyal following for his on-line program Yo! Dr. Yo as he engages the audience with live discussions on popular health and wellness topics. On the show, Mr. Purcell will discuss Generex’ progress with developing the Ii-Key-SARS-CoV-2 II-Key COVID-19 vaccine and the power of the Ii-Key platform for vaccine development. He will also discuss the signed agreements with international partners to finalize development and commercialize the Ii-Key vaccine for global markets.

Mr. Purcell provided an overview of Generex’ vaccine development, “For our COVID-19 vaccine program, we manufactured 33 targeted peptide epitopes from the spike and membrane proteins of the SARS-CoV-2 virus and linked them with our patented Ii-Key. We are finishing the screening of these 33 Ii-Key epitopes using ex-vivo human studies, whereby we test Ii-Key-SARS-CoV-2 epitopes against blood samples from patients who have recovered from COVID-19. Using this proprietary screening method, we can identify how each Ii-Key epitope regulates the immune system through T cell and B cell recognition, which allows us to select the targeted and specific Ii-Key-SARS-CoV-2 epitopes to include in the vaccine formulation. The results of the ex-vivo human blood screen to date are very encouraging, with demonstrated T helper cell activation, no Th2 response, and positive antibody binding in serum. Through targeted immune system regulation, we are developing the Ii-Key COVID vaccine as a “Complete Vaccine” that activates both the cellular and humoral (antibody) responses to provide long-term immune memory for protection from SARS-CoV-2 infection and COVID-19.”

About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

About NuGenerex Immuno-Oncology
NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines for cancer and infectious disease based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors for the treatment of cancer. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer. The company has also turned its Ii-Key technology on infectious disease, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine development program.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato
646-599-6222

Todd Falls
1-800-391-6755 Extension 222

investor@generex.com